&lt;p&gt;Pulmonary delivery of transferrin receptors targeting peptide surface-functionalized liposomes augments the chemotherapeutic effect of quercetin in lung cancer therapy&lt;/p&gt;

Riaz, Muhammad Kashif; Zhang, Xue; Wong, Ka Hong; Chen, Huoji; Qiang, Liu; Chen, Xiaoyu; Zhang, Ge; Lu, Aiping; Yang, Zhijun

doi:10.2147/ijn.s192219

Cited by 80 publications

(37 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study indicated that a 2% peptide density for T7-QR-lip resulted in a significant inhibition in lung tumor spheroids growth. Inhibition of tumor growth and prolongation of lifespan after T7-QR-lip treatment through pulmonary administration was also confirmed with in vivo studies [140].…”

Section: Liposomessupporting

confidence: 54%

Advancing of Cellular Signaling Pathways in Respiratory Diseases Using Nanocarrier Based Drug Delivery Systems

Mehta

Dhanjal

Satija

et al. 2020

CPD

View full text Add to dashboard Cite

: Cell Signaling pathways form an integral part of our existence, that allows the cells to comprehend a stimulus and respond back. Such reactions, to external cues from the environment, are required and are essential to regulate the normal functioning of our body. Abnormalities in the system arise when there are errors developed in these signals, resulting in a complication or a disease. Presently, respiratory diseases contribute to being the third leading cause of morbidity worldwide. According to the current statistics, over 339 million people who are asthmatic, 65 million who are suffering from COPD, 2.3 million who are lung cancer patients and 10 million are tuberculosis patients. This toll of statistics with chronic respiratory diseases leaves a heavy burden on society and nation annual health expenditure. Hence, a better understanding of the processes governing these cellular pathways will enable us to treat and manage these deadly respiratory diseases effectively. Moreover, it is important to comprehend the synergy and interplay of the cellular signaling pathways in respiratory diseases, which will enable us to explore and develop suitable strategies for targeted drug delivery. This review, in particular, focuses on the major respiratory diseases and further provides an in-depth discussion on the various cell signaling pathways that are involved in the pathophysiology of respiratory diseases. Moreover, the review also analyses the defining concepts about advanced nano-drug delivery systems involving various nanocarriers and propose newer prospects to minimize the current challenges faced by researchers and formulation scientists.

show abstract

Section: Liposomessupporting

confidence: 54%

Advancing of Cellular Signaling Pathways in Respiratory Diseases Using Nanocarrier Based Drug Delivery Systems

Mehta

Dhanjal

Satija

et al. 2020

CPD

View full text Add to dashboard Cite

show abstract

“…Lung cancer, predominantly non-small-cell lung cancer (NSCLC), is one of the most common types of malignant cancer and the primary cause of tumor-associated mortality and morbidity worldwide with a high incidence rate and a 5-year survival rate of 18% (1). Platinum-based chemotherapy regimens are currently the standard adjuvant treatment strategy for advanced NSCLC following surgical resection (2).…”

Section: Introductionmentioning

confidence: 99%

Knockdown of lncRNA ANRIL inhibits the development of cisplatin resistance by upregulating miR‑98 in lung cancer cells

et al. 2020

View full text Add to dashboard Cite

Emerging evidence has demonstrated that abnormally expressed long non-coding (lnc) RNAs contribute to drug resistance in various types of malignancy. LncRNA antisense non-coding RNA in the inhibitor of cyclin-dependent kinase 4 locus (ANRIL) exerts oncogenic activity and acts as a key player in a variety of carcinomas, including non-small cell lung cancer. The present study aimed to investigate the functional roles of ANRIL in cisplatin (DDP) resistance of lung cancer and the underlying mechanism involved in the competing endogenous RNA regulatory network. The expression levels of ANRIL and microRNA (miR)-98 in lung cancer tissues and DDP-resistant lung cancer cells were assessed by reverse transcription-quantitative (RT-q) PCR. The Pearson's correlation coefficient was used to determine the correlation between the expression levels of ANRIL and miR-98 in lung cancer tissues. Cell proliferation and apoptosis were detected by MTT assay and flow cytometry analysis, respectively. The expression levels of proliferation-and apoptosis-associated proteins were detected by western blot analysis. The potential interaction between ANRIL and miR-98 was confirmed by RNA immunoprecipitation (RIP), dual luciferase reporter assay and RT-qPCR. The results of the present study demonstrated that ANRIL was upregulated and miR-98 was downregulated in lung cancer tissues and A549/DDP cells. In addition, the Pearson's correlation analysis revealed that the expression of ANRIL was significantly negatively correlated with that of miR-98 in lung cancer tissues. ANRIL overexpression reversed the DDP-induced cell proliferation suppression and apoptosis in lung cancer cells, whereas ANRIL knockdown exhibited the opposite effects. RIP, dual luciferase reporter assay and RT-qPCR analysis results demonstrated that ANRIL directly interacted with miR-98 and suppressed miR-98 expression. Furthermore, transfection with the miR-98 mimics promoted DDP-induced cell proliferation inhibition and apoptosis in lung cancer cells, and these effects were partially reversed by ANRIL overexpression. In conclusion, ANRIL knockdown inhibited the development of DDP resistance by upregulating miR-98, providing novel insights into the molecular mechanism of ANRIL involvement in DDP resistance of lung cancer cells.

show abstract

“…These liposomes were evaluated for cellular uptake and in vitro cytotoxicity study and they exhibited higher cytotoxicity and S-phase cell cycle arrest. The in vivo study showed enhanced liposomes accumulation in the lungs and sustained release up to 96 h [184].…”

Section: Organic Nanoparticlesmentioning

confidence: 90%

Onco-Receptors Targeting in Lung Cancer via Application of Surface-Modified and Hybrid Nanoparticles: A Cross-Disciplinary Review

et al. 2021

View full text Add to dashboard Cite

Lung cancer is among the most prevalent and leading causes of death worldwide. The major reason for high mortality is the late diagnosis of the disease, and in most cases, lung cancer is diagnosed at fourth stage in which the cancer has metastasized to almost all vital organs. The other reason for higher mortality is the uptake of the chemotherapeutic agents by the healthy cells, which in turn increases the chances of cytotoxicity to the healthy body cells. The complex pathophysiology of lung cancer provides various pathways to target the cancerous cells. In this regard, upregulated onco-receptors on the cell surface of tumor including epidermal growth factor receptor (EGFR), integrins, transferrin receptor (TFR), folate receptor (FR), cluster of differentiation 44 (CD44) receptor, etc. could be exploited for the inhibition of pathways and tumor-specific drug targeting. Further, cancer borne immunological targets like T-lymphocytes, myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), and dendritic cells could serve as a target site to modulate tumor activity through targeting various surface-expressed receptors or interfering with immune cell-specific pathways. Hence, novel approaches are required for both the diagnosis and treatment of lung cancers. In this context, several researchers have employed various targeted delivery approaches to overcome the problems allied with the conventional diagnosis of and therapy methods used against lung cancer. Nanoparticles are cell nonspecific in biological systems, and may cause unwanted deleterious effects in the body. Therefore, nanodrug delivery systems (NDDSs) need further advancement to overcome the problem of toxicity in the treatment of lung cancer. Moreover, the route of nanomedicines’ delivery to lungs plays a vital role in localizing the drug concentration to target the lung cancer. Surface-modified nanoparticles and hybrid nanoparticles have a wide range of applications in the field of theranostics. This cross-disciplinary review summarizes the current knowledge of the pathways implicated in the different classes of lung cancer with an emphasis on the clinical implications of the increasing number of actionable molecular targets. Furthermore, it focuses specifically on the significance and emerging role of surface functionalized and hybrid nanomaterials as drug delivery systems through citing recent examples targeted at lung cancer treatment.

show abstract

<p>Pulmonary delivery of transferrin receptors targeting peptide surface-functionalized liposomes augments the chemotherapeutic effect of quercetin in lung cancer therapy</p>

Cited by 80 publications

References 60 publications

Advancing of Cellular Signaling Pathways in Respiratory Diseases Using Nanocarrier Based Drug Delivery Systems

Advancing of Cellular Signaling Pathways in Respiratory Diseases Using Nanocarrier Based Drug Delivery Systems

Knockdown of lncRNA ANRIL inhibits the development of cisplatin resistance by upregulating miR‑98 in lung cancer cells

Onco-Receptors Targeting in Lung Cancer via Application of Surface-Modified and Hybrid Nanoparticles: A Cross-Disciplinary Review

Contact Info

Product

Resources

About